Informations:
Erreur:
ID
12965
Description
Docetaxel, Vinorelbine and Trastuzumab in the Treatment of Patients With Metastatic Her-2 Positive Breast Cancer; ODM derived from: https://clinicaltrials.gov/show/NCT00193089
Lien
https://clinicaltrials.gov/show/NCT00193089
Mots-clés
Versions (1)
- 07/01/2016 07/01/2016 -
Téléchargé le
7 janvier 2016
DOI
Pour une demande vous connecter.
Licence
Creative Commons BY 4.0
Modèle Commentaires :
Ici, vous pouvez faire des commentaires sur le modèle. À partir des bulles de texte, vous pouvez laisser des commentaires spécifiques sur les groupes Item et les Item.
Groupe Item commentaires pour :
Item commentaires pour :
Vous devez être connecté pour pouvoir télécharger des formulaires. Veuillez vous connecter ou s’inscrire gratuitement.
Eligibility Breast Cancer NCT00193089
Eligibility Breast Cancer NCT00193089
- StudyEvent: Eligibility
Similar models
Eligibility Breast Cancer NCT00193089
- StudyEvent: Eligibility
Name
Type
Description | Question | Decode (Coded Value)
Type de données
Alias
biopsy metastasis
Item
metastatic breast cancer confirmed by biopsy
boolean
C0005558 (UMLS CUI [1,1])
C0027627 (UMLS CUI [1,2])
C0027627 (UMLS CUI [1,2])
her2 overexpression
Item
overexpression of the her-2 oncogene
boolean
C1960398 (UMLS CUI [1])
age
Item
age > 18 years
boolean
C0001779 (UMLS CUI [1])
measurable disease
Item
measurable disease
boolean
C1513041 (UMLS CUI [1])
performance status
Item
able to perform activities of daily living with minimal assistance
boolean
C1518965 (UMLS CUI [1])
chemotherapy
Item
no previous chemotherapy for metastatic disease
boolean
C0392920 (UMLS CUI [1])
hormone therapy
Item
one or more previous hormonal therapies for metastatic disease.
boolean
C0279025 (UMLS CUI [1])
bone marrow, liver and kidney function
Item
adequate bone marrow, liver and kidney function
boolean
C0232741 (UMLS CUI [1])
C0005953 (UMLS CUI [2])
C0232804 (UMLS CUI [3])
C0005953 (UMLS CUI [2])
C0232804 (UMLS CUI [3])
peripheral neuropathy
Item
patients with < grade 1 peripheral neuropathy are eligible.
boolean
C0031117 (UMLS CUI [1])
informed consent
Item
must give written informed consent prior to entering this study.
boolean
C0021430 (UMLS CUI [1])
cardiac function
Item
abnormal heart function
boolean
C0232164 (UMLS CUI [1])
trastuzumab
Item
previous treatment with trastuzumab
boolean
C0338204 (UMLS CUI [1])
brain metastases
Item
brain metastases untreated
boolean
C0220650 (UMLS CUI [1])
peripheral neuropathy
Item
pre-existing symptomatic peripheral neuropathy
boolean
C0031117 (UMLS CUI [1])
comorbidity
Item
serious underlying medical conditions
boolean
C0009488 (UMLS CUI [1,1])
C0205082 (UMLS CUI [1,2])
C0205082 (UMLS CUI [1,2])
additional inclusion/exclusion criteria
Item
please note: there are additional inclusion/exclusion criteria. the study center will determine if you meet all of the criteria. if you do not qualify for the trial, study personnel will explain the reasons. if you do qualify, study personnel will explain the trial in detail and answer any questions you may have.
boolean